Restoring CYP46A1 activity and cholesterol homeostasis through allosteric modulation or viral vector delivery is a therapeutic goal in Huntington's disease (ClinicalTrials.gov: NCT05541627). The gene discussed is CYP46A1; the disease is juvenile Huntington disease.